A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01479647
First received: November 22, 2011
Last updated: February 25, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the effect of food on the time course of PH-797804 concentration in the blood following dosing by oral immediate release tablet formulation.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Volunteers |
Drug: PH-797804 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | A Phase 1, Randomized, Open-Label, Single Dose, 2-Cohort Crossover Study To Determine The Effect Of Food On The Pharmacokinetics Of Orally Administered PH-797804 In Healthy Volunteers |
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Pharmacokinetics: peak plasma concentration [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose ] [ Designated as safety issue: No ]
- Pharmacokinetics: time to peak plasma concentration [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose ] [ Designated as safety issue: No ]
- Pharmacokinetics: area under the plasma concentration-time curve [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose ] [ Designated as safety issue: No ]
- Pharmacokinetics: terminal plasma half-life [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose ] [ Designated as safety issue: No ]
| Enrollment: | 28 |
| Study Start Date: | December 2011 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PH-797804 1 mg Fasted
Subjects will receive a single 1 mg dose in the fasted state
|
Drug: PH-797804
Tablet, 1 mg, single dose
|
|
Experimental: PH-797804 1 mg Fed
Subjects will receive a single 1 mg dose following a high-fat meal
|
Drug: PH-797804
Tablet, 1 mg, single dose
|
|
Experimental: PH-797804 10 mg Fasted
Subjects will receive a single 10 mg dose in the fasted state
|
Drug: PH-797804
Tablet, 10 mg, single dose
|
|
Experimental: PH-797804 10 mg Fed
Subjects will receive a single 10 mg dose following a high-fat meal
|
Drug: PH-797804
Tablet, 10 mg, single dose
|
|
Experimental: PH-797804 24 mg Fed
Subjects will receive a single 24 mg dose following a high-fat meal
|
Drug: PH-797804
Tablet, 24 mg, single dose
|
Eligibility| Ages Eligible for Study: | 21 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy male subjects and/or healthy female subjects of non-child bearing potential between the ages of 21 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lbs).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 21 drinks/week for males.
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT01479647 History of Changes |
| Other Study ID Numbers: | A6631034 |
| Study First Received: | November 22, 2011 |
| Last Updated: | February 25, 2012 |
| Health Authority: | Singapore: Health Sciences Authority |
ClinicalTrials.gov processed this record on June 17, 2013